{"id":"W4212780237","doi":"10.1200/jco.2022.40.6_suppl.012","title":"Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Abiraterone acetate; Enzalutamide; Oncology; Progression-free survival; Cancer; Androgen deprivation therapy; Androgen receptor; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002495393,0.0002710178,0.001401822,0.0002813162,0.0001886691,0.00002270423,0.0001040277,0.00008377186,0.00005894652],"category_scores_gemma":[0.0002452209,0.0001790818,0.00007212204,0.0003863501,0.0003959035,0.0002601509,0.00003895192,0.0007312207,3.455934e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003167223,"about_ca_system_score_gemma":0.001271429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002995739,"about_ca_topic_score_gemma":0.003042579,"domain_scores_codex":[0.9955411,0.0007618254,0.002271755,0.000454565,0.0007136751,0.0002570545],"domain_scores_gemma":[0.9955055,0.0005561537,0.002579627,0.0002684256,0.0008687784,0.0002214981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4078828,0.02864613,0.5135117,0.0001473063,0.002036621,0.0008813512,0.005257714,0.00339429,0.0005081762,0.00001048014,0.0003319662,0.03739149],"study_design_scores_gemma":[0.2617451,0.3602795,0.3726387,0.0003100245,0.0006417203,0.0005136993,0.0007581025,0.0003533793,0.0005284859,0.00008971786,0.001870648,0.0002708873],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935595,0.0005084386,0.00006126238,0.003659579,0.0001534405,0.001884567,0.0001054203,0.00001735775,0.00005042055],"genre_scores_gemma":[0.9917918,0.001457139,0.005681657,0.000528049,0.00007769161,0.0002485818,0.00003912117,0.00003962348,0.0001362869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3316334,"threshold_uncertainty_score":0.7302746,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08166941178403357,"score_gpt":0.4274364120016267,"score_spread":0.3457670002175932,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}